Search Results

Aktis Oncology today announced the promotion of Tyler Benedum, Ph.D., to Chief Technical Officer, effective immediately.

Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.

Eli Lilly is paying $60 million upfront to Aktis Oncology to discover and develop novel tumor-targeting radiopharmaceuticals, as radiopharma dealmaking continues to heat up in 2024.

Aktis Oncology, a clinical-stage biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the appointment of Ken Herrmann, MD, MBA, to the Company’s Board of Directors.

Aktis Oncology, a clinical biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced that Matthew Roden, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024 at 9:20 a.m. ET.

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced that Matthew Roden, Ph.D., President and Chief Executive Officer, will be presenting at the 2024 Guggenheim Healthcare Talks Radiopharmaceuticals Day, being held Monday, May 13, 2024, in New York City.

Aktis Oncology, a biotechnology company discovering and developing novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announces an oral presentation at the Oligonucleotide & Peptide Therapeutics Conference 2024, being held May 14-17, 2024, in Boston, Mass. and virtually.

Aktis Oncology today announced that Matthew Roden , Ph.D., President and Chief Executive Officer, and Shulamit Ron-Bigger , Ph.D., Chief Operating Officer of Aktis Oncology, will participate in Investor meetings at the TD Cowen 44th Annual Healthcare Conference in Boston, Mass. on Monday, March 4, 2024.